< Back to the team

B. Pinteur

Founder & Chief Scientific Officer

STC technology inventor
Specialized in innovative cellular therapies Pharmaceutical development expert (Early R&D, QA/QC & development).

Benoît Pinteur (Chief Scientific Officer, PharmD) brings 25 years of experience in the pharma industry with roles at Shering-Plough and Roche, mainly in pharmaceutical development.

From previous collaboration with international teams on autologous cancer immunotherapy (ERC Belgium), he decided to create Brenus Pharma, with the STC Technology, to address previous limitations of immune therapeutics approach.

Benoit was formerly the CEO of BioElpida, a CDMO where he developed expertise in ATMP and GMP manufacturing with a special focus on immunotherapies, cell therapies and vaccines.

Linkedin-in

INCREASE IMMUNOGENICITY

Brenus’ manufacturing process overpasses the lack of immunogenicity & educates the immune system  with visible and multi-specific targets

More about Haptenization & STC immunogenicity
Back to the page

REPRESENT HETEROGENEITY OF THE TARGETED INDICATION

Selection criteria of starting material (Allogeneic tumor cell lines)

  • Representative oncogenic drivers (TP53,BRAF,KRAS,…)
  • Cold & hot tumor cell lines
  • Resistances capacities (metabolic ; chemical & physical)
Back to the page

Increase antigenicity

Brenus’ manufacturing process overpasses the lack of antigenicity & educates the immune system  with a broad & higher quality range of tumor antigens

More about STC Antigenicity
Back to the page